Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?
Restricted accessEditorialFirst published online June, 2017
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?
TuttleM, MorrisLF, HaugenB, ShahJ, SosaJA, RohrenE, SubramaniamRM, HuntJL, PerrierND. 2017. Thyroid-differentiated and anaplastic carcinoma. In: AminMB, EdgeSB, GreeneF, ByrdD, BrooklandRK, WashingtonMK, GershenwaldJE, ComptonCC, HessKR, SullivanDC, JessupJM, BrierleyJ, GasparLE, SchilskyRL, BalchCM, WinchesterDP, AsareEA, MaderaM, GressDM, MeyerLR, (eds) AJCC Cancer Staging Manual. Eighth edition. Springer International Publishing, New York, New York.
2.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
3.
MomessoDP, TuttleRM. 2014. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am, 43:401–421.
4.
NixonIJ, WangLY, MigliacciJC, EskanderA, CampbellMJ, AnissA, MorrisL, VaismanF, CorboR, MomessoD, VaismanM, CarvalhoA, LearoydD, LeslieWD, NasonRW, KukD, WreesmannV, MorrisL, PalmerFL, GanlyI, PatelSG, SinghB, TuttleRM, ShahaAR, GonenM, PathakKA, ShenWT, SywakM, KowalskiL, FreemanJ, PerrierN, ShahJP. 2016. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid, 26:373–380.
5.
GanlyI, NixonIJ, WangLY, PalmerFL, MigliacciJC, AnissA, SywakM, EskanderAE, FreemanJL, CampbellMJ, ShenWT, VaismanF, MomessoD, CorboR, VaismanM, ShahaA, TuttleRM, ShahJP, PatelSG. 2015. Survival from differentiated thyroid cancer: what has age got to do with it?. Thyroid, 25:1106–1114.
6.
HayID, BergstralhEJ, GoellnerJR, EbersoldJR, GrantCS. 1993. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114:1050–1057; discussion 1057–1058.
7.
PathakKA, MazuratA, LambertP, KlonischT, NasonRW. 2013. Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab, 98:4768–4775.
8.
AdamMA, ThomasS, HyslopT, ScheriRP, RomanSA, SosaJA. 2016. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol, 34:4415–4420.
9.
AdamMA, PuraJ, GoffredoP, DinanMA, ReedSD, ScheriRP, HyslopT, RomanSA, SosaJA. 2015. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol, 33:2370–2375.
10.
VerburgFA, MaderU, TanaseK, ThiesED, DiesslS, BuckAK, LusterM, ReinersC. 2013. Life expectancy is reduced in differentiated thyroid cancer patients >/ = 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab, 98:172–180.
